Répertoire des ingrédients

β-Gal-(1→3)-β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1↔1')-Cer(2−)

An anionic ganglioside obtained by deprotonation of the neuraminosyl carboxy groups of β-Gal-(1→3)-β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1↔1')-Cer; major species at pH 7.3.

β-Gal-(1→3)-β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1↔1')-Cer(d18:1/18:0)

A β-Gal-(1→3)-β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1↔1')-Cer in which the ceramide N -acyl group is specified as octadecanoyl.

β-Gal-(1→3)-β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1↔1')-Cer(d18:1/18:0)(2−)

An anionic ganglioside obtained by deprotonation of the neuraminosyl carboxy groups of ganglioside GD1b(d18:1/C18:0); major species at pH 7.3.

β-Gal-(1→3)-β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1↔1')-Cer

A sialotetraosylceramide consisting of a branched heptasaccharide made up from three sialyl residues, two galactose residues, one N -acetylglucosamine residue and a glucose residue at the reducing end attached to the ceramide portion via a β-linkage.

β-Gal-(1→3)-β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1↔1')-Cer(3−)

An anionic ganglioside obtained by deprotonation of the neuraminosyl carboxy groups of ganglioside GT1c; major species at pH 7.3.

β-Gal-(1→4)-[α-Fuc-(1→3)]-β-GlcNAc-(1→3)-β-Gal-(1→4)-β-Glc-(1→1')-Cer

β-Gal-(1→4)-α-GalNAc-(1→3)-[α-Fuc-(1→2)]-β-Gal-(1→4)-β-GlcNAc-(1→3)-β-Gal-(1→4)-β-Glc-(1→1')-Cer

β-GalNAc-(1→4)-[α-Neu5Ac-(2→3)]-β-Gal-(1→3)-β-GlcNAc-(1→3)-β-Gal-(1→4)-β-Glc-(1→1')-Cer

β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-R group

An organic group forming part of, and a proposed epitope within, ganglioside G D2 . The -(1→4)-R in the name may represent -(1→4)-glucosyl.

β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1↔1')-Cer(2−)

An anionic ganglioside obtained by deprotonation of the neuraminosyl carboxy groups of β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1↔1')-Cer; major species at pH 7.3.

β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1→1')-Cer

A sialotriaosylceramide consisting of the hexasaccharide β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc attached to the primary hydroxy function of ceramide.

β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1→1')-Cer(3−)

An anionic ganglioside obtained by deprotonation of the neuraminosyl carboxy groups of ganglioside GT2; major species at pH 7.3.

β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1→1')-Cer(d18:1/16:0)

A sialotriaosylceramide consisting of the hexasaccharide β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc attached to the primary hydroxy function of ceramide(d18:1/16:0).

β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc-(1→1')-Cer(d18:1/18:0)

A sialotriaosylceramide consisting of the hexasaccharide β-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-Gal-(1→4)-β-Glc attached to the primary hydroxy function of ceramide(d18:1/18:0).

β-GalNAc-(1→4)-[α-NeuGc-(2→8)-NeuGc-(2→3)]-β-Gal-(1→4)-β-Glc-(1→1')-Cer

β-Glc p -(1→6)-{β-Glc p -(1→6)-{[β-Glc p -(1→3)] 5 }-[β-Glc p -(1→3)] 5 }-[β-Glc p -(1→3)] 4 -β-Glc p

A β- D -glucan consisting of [3)-β- D -Glc p -(1→] 15 in which the fifth and tenth glucosides from the reducing end are substituted at position 6 by β- D -glucoside residues.

β-GlcNAc-(1→4)-MurNAc- L -Ala-γ- D -Glu- L -Lys-( D -Ala) 2

An N -acetyl-β- D -glycosaminyl glycopeptide consisting of an N -acetyl-β- D -glycosaminyl-(1→4)- N -acetylmuramoyl moiety attached to the amino terminus of the pentapeptide L -Ala-γ- D -Glu- L -Lys- D -Ala- D -Ala via an amide linkage.

β-GlcNAc-(1→4)-MurNAc- L -Ala-γ- D -Glu- N 6 -(β- D -Asp)- L -Lys-( D -Ala) 2

An N -acetyl-β- D -glycosaminyl glycopeptide consisting of an N -acetyl-β- D -glycosaminyl-(1→4)- N -acetylmuramoyl moiety attached to the amino terminus of the pentapeptide L -Ala-γ- D -Glu- N 6 -(β- D -Asp)- L -Lys- D -Ala- D -Ala via an amide linkage.

β-MurNAc-(1→4)-β- D -Glc p NAc

An amino disaccharide comprising an N -acetyl-β-muramyl residue linked (1→4) to N -acetyl-β- D -glucosamine.

β-Neu p 5Gc-(2→6)-β- D -Gal p -(1→4)- D -Glc p NAc

A linear amino trisaccharide comprising an N -glycoloyl-β-neuraminyl residue (2→6)-linked to a β- D -galactosyl residue, which is in turn linked (1→4) to N -acetyl-β- D -glucosamine.

β-Neu p NAc-(2→6)-β- D -Gal p -(1→4)-β- D -Glc p NAc

An amino trisaccharide consisting of an N -acetyl-β-neuraminyl residue attached to the galactose residue of N -acetyllactosamine via an α-(2→6)-linkage.

β-acoradiene

A spiro compound that is 1,8-dimethyl-4-(prop-1-en-2-yl)spiro[4.5]decane that has been dehydrogenated to introduce a double bond at position 8-9 (the 1 R ,4 S ,5 R isomer).

β-adrenergic agonist

An agent that selectively binds to and activates β-adrenergic receptors.

β-adrenergic antagonist

An agent that binds to but does not activate β-adrenergic receptors thereby blocking the actions of endogenous or exogenous β-adrenergic agonists. β-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.